


Our mission

Alere offers best-in-class rapid diagnostics that enable healthcare professionals to distinguish between respiratory tract infections that require treatment and those that are self-limiting, as well as several other diagnostic tools that can help clinicians identify pathogens and define an appropriate treatment strategy earlier. These include solutions for Strep A, Influenza, *S. pneumoniae*, MRSA and *C. difficile*. By supplying healthcare providers with comprehensive diagnostic information, Alere empowers a shift in treatment trends; moving away from the broad over-prescription of antibiotics, which contributed to the growing prevalence of serious healthcare-associated infections, towards a more targeted therapy.



How will rapid diagnostics benefit your patients?
Discover more at
TestTargetTreat.com today.



**TEST
TARGET
TREAT™**



Alere International Limited
Parkmore East Business Park
Ballybrit, Galway, Ireland
P: +353 (0) 91 429 900
F: +353 (0) 91 429 999
alere.com

1. Cals, J.W. et al. (2009) Effect of point of care testing for C reactive protein and training in communication skills on antibiotic use in lower respiratory tract infections: cluster randomised trial. *BMJ*. 2009; 338(51):1374. [Online] doi:10.1136/bmj.b1374.
2. Lasseter, G.M. et al. (2009) In vitro evaluation of five rapid antigen detection tests for group A beta-haemolytic Streptococcal sore throat infections. *Family Practice*, 1-8.
3. Yago, J. (2008) We Must Use Rapid Antigen Techniques to Treat Infectious Diseases in the Primary Care Clinic. *Aten Primaria*, 40(10):489-96.
4. Bonner, A.B. et al. Impact of the Rapid Diagnosis of Influenza on Physician Decision-Making and Patient Management in the Pediatric Emergency Department: Results of a Randomized, Prospective, Controlled Trial. *Pediatrics*. 2003 Vol. 112 No. 2.
5. Weatherall, C., Paoloni, R. and Gottlieb, T. (2008) Point-of-care urinary pneumococcal antigen test in the emergency department for community acquired pneumonia. *Emerg Med J*, 25(3):144-8.
6. File Jr, T.M. and Kozlov, R.S. (2006) Rapid detection of *Streptococcus pneumoniae* in community-acquired Pneumonia. *Clin Microbiol Infect*, 12 (suppl 9): 27-33.
7. Lodise, T.P. and McKinnon, P.S. (2005) Clinical and economic impact of methicillin resistance in patients with *Staphylococcus aureus* bacteremia. *Diagnostic Microbiology and Infectious Disease*, Vol.52, pp.113-122 [Online] doi:10.1016/j.diagmicrobio.2005.02.007.
8. U.K. Department of Health. Updated guidance on the diagnosis and reporting of *C. difficile*. 2012.
9. Pennington, H. (2010) *Escherichia coli* O157. *The Lancet*, Vol.376, pp.1428-35.
10. Johnson, K.E., Thorpe, C.M. and Sears, C.L. (2006) The emerging clinical importance of non-O157 Shiga Toxin-producing *Escherichia coli*. *Clinical Infectious Diseases*, Vol. 43, pp.1587-95.
11. World Health Organization (WHO), WHO Malaria Report 2013. [Online] Accessed: 03 Jun 14. Available at: http://www.who.int/malaria/publications/world_malaria_report_2013/report/en/.
12. World Health Organization (WHO), Malaria Fact Sheet. [Online] Accessed 01 Jun 17. Available at <http://www.who.int/mediacentre/factsheets/fs094/en/>
13. Malaria Diagnostics Technology and Market Landscape. 3rd Edition. April 2016.

© 2017 Alere. All rights reserved. The Alere Logo, Alere, Afinion, BinaxNOW, Knowing now matters and Test Target Treat are trademarks of the Alere group of companies. C. DIFF QUIK CHEK COMPLETE and SHIGA TOXIN QUIK CHEK are trademarks of TECHLAB, Inc. under license. IFD15580 12000884-05 10/17




Knowing now matters.™

What doesn't kill them makes them stronger.



**TEST
TARGET
TREAT™**



The misuse of antibiotics has created a huge global health crisis.



The Test Target Treat™ initiative from Alere empowers healthcare professionals to make targeted treatment decisions sooner with rapid diagnostics—reducing inappropriate antimicrobial use and the spread of resistance.



Empowering appropriate antimicrobial use with rapid diagnostics.

Vero-cytotoxin Toxin-producing *E. coli* (VTEC)



Sub-optimal diagnosis for VTEC infection can result in the unnecessary prescription of antibiotics that can result in adverse clinical consequences as well as the growing problem of resistance. Prompt detection is necessary to prevent outbreaks and to direct appropriate treatment therapies.^{9,10} The *SHIGA TOXIN QUIK CHEK™* test from Alere (developed and manufactured by TechLab®, Inc.) is a rapid test able to detect VTEC/STEC toxins from all common sub-types directly from fecal samples in under 30 minutes.

Pneumonia



The early and rapid diagnosis of pneumonia can allow more directed therapy and confidence in appropriate treatment for a majority of patients.⁵ Using an appropriate pathogen-focused antibiotic or narrowing empirical therapy can decrease cost, drug adverse events, and the threat of antibiotic resistance.⁶ The Alere BinaxNOW® *Streptococcus pneumoniae* and Alere BinaxNOW® *Legionella* urine antigen tests are highly specific, rapid and simple to use tools to aid in the diagnosis and treatment of these two leading causes of pneumonia.

Point of care C-reactive Protein (CRP)



The use of point of care tests for CRP have been shown to significantly reduce antibiotic prescribing for lower respiratory tract infections (RTIs) without compromising patient recovery or satisfaction with care.¹ Alere Afinion™ CRP helps discriminate serious illness such as pneumonia from often self-limiting illness like acute bronchitis and other RTIs.¹

Malaria



Between 2010 and 2015, the children under five malaria death rate fell by 29% globally. However, malaria remains a major killer of children under five years old, taking the life of a child every two minutes, even though it is a preventable and curable disease.¹² Since it has become clear that continued presumptive treatment of malaria will lead to both drug wastage and under-treatment of other febrile illnesses, the World Health Organization (WHO) recommends that every suspected malaria case be confirmed by microscopy or a rapid diagnostic test (RDT) prior to treatment.¹¹ The Alere portfolio of Malaria RDTs includes the most widely used tests in Africa and Asia (SD BIOLINE).¹³

Pharyngitis




Rapid tests to identify Strep A pharyngitis can reduce unnecessary antibiotic prescribing and antimicrobial resistance by enabling appropriate treatment for positive cases.^{2,3} The Alere portfolio of Strep A Pharyngitis products can provide highly accurate results in as little as 5 minutes and are easy to use in a variety of settings. The **Alere™ i** Strep A molecular test provides accurate results in 8 minutes or less.

Influenza



A positive rapid influenza test result enables antibiotics to be withheld and antivirals to be prescribed where appropriate. Traditional diagnosis of influenza by viral culture or polymerase chain reaction (PCR) is too lengthy to be useful for effective treatment options.⁴ **Alere™ i** Influenza A & B is a molecular flu test that provides results in 15 minutes or less.

C. difficile



Clostridium difficile infection (CDI) is the most common cause of hospital acquired, infectious diarrhea and generally occurs when patients have been treated with antibiotics. The latest ESCMID guidelines⁹ published in 2016 recommend to screen samples simultaneously with both a GDH and toxin A/B EIA with an assay that includes both targets in one system. The C. DIFF QUIK CHEK COMPLETE® test detects and differentiates GDH and toxins A/B simultaneously in less than 30 minutes.

Respiratory Syncytial Virus (RSV)



RSV symptoms are similar to those of other common respiratory infections. Patients presenting with these symptoms are often treated empirically with antibiotics, without a formal diagnosis. An accurate diagnosis allows infection control measures to be implemented, and enables the physician to withhold antibiotics, which are not effective against viruses. **Alere™ i** RSV aids in the rapid diagnosis of RSV in just 13 minutes or less.

S. aureus and Methicillin resistant *S. aureus* (MRSA)



It is essential that *S. aureus* and MRSA infections are identified as early as possible and steps are taken to ensure the correct treatment is implemented. Rapid testing aids in reducing the empirical use of Vancomycin and permits cost-effective decisions for optimal patient management.⁷ The Alere™ PBP2a SA Culture Colony Test assists in the detection of MRSA directly from bacterial isolates in 5 minutes.